Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disorder characterized by strictures and dilatations of the biliary tree. The median survival has been reported to be 12 years from diagnosis but patients diagnosed during the last decade have been shown to have longer survival of a median of 18 years. Small duct PSC seems to be an entity of its own and rarely progresses to large duct PSC and the prognosis of small duct PSC is much better than in large duct disease. Cholangiocarcinoma does not develop in patients with small duct PSC according to recently published studies. Autoantibodies binding to biliary epithelial cells have been demonstrated in sera from patients with PSC but the pathogenic role of these remains to be determined. It is suggested that inflammatory bowel disease is accelerated after orthotopic liver transplantation. MR cholangiopancreatography is increasingly used in clinical practice and has been reported to have similar diagnostic accuracy as ERCP. However, lack of standardization of this novel technology makes it unclear if it can supersede ERCP as a diagnostic tool in PSC at the present time. Better diagnostic tests to detect cholangiocarcinoma in patients with PSC are urgently needed. Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disorder with fibrosis of the intrahepatic or extrahepatic bile ducts. PSC is characterized by progressive periductal obliterating fibrosis and bile duct strictures. In individual cases, PSC can follow a benign course. In most cases, however, it is a progressive disorder, associated with loss of functioning bile ducts. It is complicated by cholangiocarcinoma in 10% to 20% of cases, which is difficult to diagnose. The etiopathogenesis is still unknown, no curative therapy is available for this disorder, and it continues to be a common indication for orthotopic liver transplantation (OLT).
Natural history and prognosis
The natural history of PSC has been well characterized in studies from the United States, the United Kingdom, and Sweden, which have included more than 600 cases and have shown remarkable similarities in survival. In these previous reports, median survival to death or liver transplantation has been estimated to be 12 years. A multicenter study from The Netherlands demonstrated an estimated median survival of 18 years from time of diagnosis to death from liver disease or liver transplantation [1••]. Earlier studies included patients mainly from the 1970s and 1980s, whereas patients in this Dutch study also included a cohort of patients between 1990 and 1999. Diagnosis of PSC might have been made earlier during the last decade and thus ascertainment bias might play a role in the results. Apart from the assessment of the natural history of PSC in a Dutch population, the aim of this study was also to evaluate the prognostic value of a cholangiographic classification system.
Only two reports in the literature have previously assessed the value of cholangiography in predicting prognosis in PSC [2, 3] . Both demonstrated that cholestasis was more associated with intrahepatic than extrahepatic changes in PSC and high-grade intrahepatic strictures were indicative of a poor prognosis. Difficulties in using cholangiography as an indicator of prognosis in PSC partly result from the fact that no consensus exists on a scoring system for cholangiographic abnormalities. The Dutch group has previously proposed and evaluated a classification of radiographic system in PSC [4]. The conclusion was that a combination of intrahepatic and extrahepatic cholangiographic scoring was closely related to survival. Higher scores were associated with a considerably poorer prognosis. This scoring system seems to be promising and might be used in the future in multicenter international studies to prospectively validate its use in PSC.
Most of the research performed and published on PSC comes from the United States, the United Kingdom, and Scandinavian countries. PSC seems to be rare in certain areas of the world. Limited data on the prevalence of PSC are available from Asia. Ang et al. reported on the clinical profile of patients with PSC in Singapore [5]. This report seems to confirm that PSC is very rare in this part of the world as only 10 cases had been identified in a population of 750,000 during a 10-year period. Comparison studies from Norway reveal an annual incidence and point prevalence of 1.3 and 8.5 per 100 000 inhabitants. Patients with PSC diagnosed in Singapore were different in many respects from the clinical profile of patients from the United States and northern Europe. The Asian patients were older at presentation; a higher proportion of patients presented with hepatobiliary sepsis and only 20% had concomitant inflammatory bowel disease (IBD). However, only half of those who were asymptomatic had colonoscopy and because IBD associated with PSC often is clinically silent, IBD could have been missed. This report is consistent with previous studies suggesting that important epidemiologic differences might exist in patients fulfilling the criteria for PSC.
The liver function tests of some patients show them to be cholestatic and to have typical histologic features of PSC but with a normal cholangiography. These patients with a clinical diagnosis of PSC, where other cholestatic disorders have been ruled out, have been identified as having small duct PSC. The natural history of small duct PSC has been unclear until now. Three different publications have described the natural history of this group of patients and the proportion of patients progressing to large duct PSC [6•,7,8•]. These studies from Sweden, the Mayo clinic, and a joint study from Oslo and Oxford produced remarkably similar results. Whereas the clinical signs and symptoms and age at presentation were very similar in patients with small and large duct PSC, those with small duct PSC had a much more favorable prognosis, with survival no different from the general population. Furthermore, they had highly significant better survival when compared with those with large duct PSC. Altogether, these three reports contained 83 patients and no patient developed cholangiocarcinoma, the most feared complication of PSC, although the follow-up was similar for patients with either small or large duct PSC. Only 13% of the patients in the present series originally considered to have small duct PSC developed large duct PSC. It is somewhat controversial whether IBD should be a prerequisite for a diagnosis of small duct PSC [7] or whether patients without evidence of IBD should also be included [6•,8•]. The proportion of patients with PSC lacking IBD is approximately 20% to 25% in published series and it thus seems illogical to limit the use of the term "small duct PSC" to those patients with IBD alone. However, perhaps more rigor-ous effort should be put into the diagnostic workup of patients without concomitant IBD to exclude other differential diagnoses, including the rare entity of idiopathic adulthood ductopenia. The results from these three studies suggest that small duct PSC is a clinical entity of its own and in most cases it is not an earlier form of large duct PSC. Data on comparison of HLA type and the prevalence of antineutrophil cytoplasmic antibody (ANCA) between patients with small and large duct PSC are not yet available, but might be important in the future for interpreting these findings.
Several prognostic models for PSC have been designed. However, prognosis in patients with PSC is particularly difficult to predict perhaps because of the highly variable clinical course. Although in most cases, PSC is a progressive disorder toward liver cirrhosis and a substantial number of patients develop the more unpredictable complication of cholangiocarcinoma, the prognostic scores are not widely used in the clinical assessment of PSC and the need for liver transplantation. A joint study from five different European countries involving 330 patients with PSC reported on a development of a time-dependent Cox regression model [9] . Bilirubin (on a logarithmic scale), albumin, and age at diagnosis were found to be independent prognostic factors in a multivariate analysis. A time-dependent Cox regression model was developed, which had the benefit of being more precise in the estimation of short-term prognosis than former traditional time-fixed models. However, prognostic models, in general, are imprecise in the assignment of survival probability for the individual patient.
Etiopathogenesis
Although the etiopathogenesis of PSC is still unknown, some important contributions to the understanding of the pathophysiology have been made during the last few years [10] . A novel rat model of fibrosing cholangitis resembling human PSC was recently described by a group of German investigators [11] . Because downregulation of hepatocellular organic anion transporters is implicated in the molecular pathogenesis of cholestasis, expression of these transporters was determined in this animal model [12] . In this model of chronic cholangitis, only canalicular Mrp2 anion transporter remained downregulated. This might represent the first injury to hepatocytes in chronic cholangitis as an extension of liver injury from the level of cholangiocytes to hepatocytes in human PSC.
Most patients with PSC have circulating ANCA and other autoantibodies are observed in most, but not all patients. Sera of patients with PSC as well as primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) were investigated for the presence of autoantibodies binding to human biliary epithelial cells (BEC) [13••]. Compared with controls (8%), significantly more patients with PSC (63%, P = 0.001) but not PBC (37%) or AIH (16%) had anti-BEC antibodies. In 90% of patients with PSC, the autoantibodies reacted only with cytokinestimulated target cells. Furthermore, anti-BEC antibodies from patients with PSC and PBC, but not AIH, induced BEC to produce high levels of interleukin 6. The results are intriguing in the sense of this demonstration of functionally important autoantibodies to cell surface expressed antigens on the relevant target cells of destruction and might throw light on the pathogenesis of bile duct destruction in PSC. These results further strengthen an autoimmune hypothesis in the pathogenesis of PSC. Further studies are needed to investigate the prognostic value of these autoantibodies against BEC.
Bile duct injury in PSC characterized by significant periductal fibrosis leading to obliterating fibrosis of the bile ducts is different from the overt destructive lesion in PBC. However, in both conditions the pathogenesis of bile duct destruction is unknown. Whereas apoptosis can be an important factor in normal cellular homeostasis, dysregulated apoptosis might be involved in the pathogenesis in cholestatic liver disease. Tinmouth et al. analyzed samples from explanted livers from patients with PSC and PBC and biliary epithelial cells were stained for markers of apoptosis [14] . Livers from patients with PBC demonstrated greater evidence of apoptosis than livers from patients with PSC. Little evidence was found for an important role of apoptosis in PSC in contrast with PBC livers with higher overall apoptosis than in PSC and in control livers.
The role of bacteria in causing the inflammatory lesion in PSC has been investigated in portal blood, bile, and explanted livers from patients with PSC, but no evidence exists to support an infectious cause of PSC. A survey of infectious agents was performed to test the hypothesis that past or persisting infection with viruses or atypical bacteria might play a role in genetically susceptible hosts [15•]. Serologic screening for antibodies against 22 viruses, as well as Chlamydia species and mycoplasma, was carried out in 41 Dutch patients with PSC. A markedly elevated seroprevalence of Chlamydia lipopolysaccharides (LPS) antibodies compared with both an IBD group and a non-IBD group was observed. However, the actual presence of Chlamydia bodies in liver tissue could not be demonstrated. No significant differences were observed regarding IgG between the groups, but in contrast, a significantly higher proportion of patients with PSC was positive with IgM and IgA than controls. The authors hypothesized that a previous contact with a microorganism (eg, Chlamydia) might induce autoantibodies that cross-react with certain parts of the bile duct system. Further studies are needed to confirm these findings and elucidate a potential role for this microorganism in PSC.
Concomitant ulcerative colitis (UC) is present in 70% to 80% of patients with PSC. It has been well documented that smoking has a protective effect in UC and a previous appendectomy or tonsillectomy has been associated with a decreased risk of developing UC. Mitchell et al. [16••] examined these factors in patients with PSC, with and without an underlying IBD. A significantly larger proportion of patients with PSC had never smoked (66%) compared with controls (39%). Only 7% of patients with PSC were current smokers versus 25% of matched controls. Only 5% of patients with PSC without IBD were smokers, suggesting an independent association between nonsmoking and PSC. The rate of previous appendectomy was similar in all groups, but the frequency of tonsillectomy was reduced in PSC (21% vs 31%, P = 0.05). The latter finding might indicate a small protective effect of tonsillectomy on the development of PSC. Medical records could not verify this clinical information, however, because tonsillectomies are usually performed in childhood and some decades before this survey was conducted and a recall bias could not be excluded. The results of this study showing that PSC, as with UC, is a disease of nonsmokers and smoking has a protective effect on the development of PSC, which seems to be independent of the presence of concomitant IBD. The role of tonsillectomy warrants further study.
An association of PSC, UC, and celiac disease was reported to be present in female siblings [17] . Both patients carried HLA molecules DR3 and DQ2. The familial occurrence of PSC supports the hypothesis of genetic predisposition for the development of PSC, UC, and celiac disease.
Clinical features
An interesting study from Pittsburgh [18•] addressed the evolution of IBD in patients with PSC who had liver transplantation. Data on 303 patients with PSC who had transplantation between 1981 and 1997 were available. The proportion of patients with PSC with concomitant IBD before transplantation was 68%. It would be assumed that the IBD after orthotopic liver transplantation (OLT) would improve, given that the patients receive potent immunosuppressive therapy for rejection prophylaxis and the hallmark of IBD treatment is immune modulation. Furthermore, cyclosporine and tacrolimus, as well as azathioprine, often used after OLT, can be effective in IBD. These researchers used advanced statistical methods and a special emphasis was placed on the course of the disease before the need for transplantation and assessment of the simultaneous effect of multiple time-dependent factors on the outcome. Surprisingly, it was shown that transplantation and concomitant use of immunosuppression accelerated the progression of IBD. The only significant risk factor in multivariate analysis for colectomy was found to be transplantation itself, which increased the risk for colectomy because of intractable disease. However, OLT did not change the risk for colorectal cancer. Previous follow-up studies on the course of IBD in patients with PSC from the United Kingdom have also demonstrated a somewhat aggressive course after OLT [19] , which is in line with results of the Pittsburgh study [18] . The authors speculated on the possible enhancement of growth of enteric organisms or antigens (eg, cytomegalovirus, which has recently been implicated in some patients with steroid refractory IBD) [20] . Alternatively, corticosteroids could have been discontinued early, a practice more common in immunosuppressive regimens containing calcineurin inhibitors. These results suggest that nonimmune pathogenic factors might be involved in patients with PSC and concomitant IBD. Further studies are needed to explore whether patients with PSC having OLT require alternative forms of immunosuppression and whether microorganisms might play a role in the course of IBD after transplantation.
A recent review on the recurrence of PSC after liver transplantation, which summarized many earlier studies on this subject, came to the conclusion that convincing evidence exists to support that PSC recurs after transplantation [21] . Both histologic evidence and cholangiographic finding suggest that PSC recurs in 5% to 20% of patients, but graft survival does not seem to be negatively affected by disease recurrence in the intermediate follow-up. More studied are needed to establish the long-term consequence of recurrence and a role for medical therapy, such as ursodeoxycholic acid.
Despite the clinical importance of osteopenia in cholestatic liver disease little is known about its pathophysiologic mechanisms. Fifty patients with PBC and PSC having OLT were studied by tetracycline-labeled histomorphic analysis of bone biopsies [22] . Both patient groups showed evidence of decreased bone formation and increased resorption, which suggests similar mechanisms in cholestatic osteopenia independent of the cause of the liver disorder. No evidence was found for osteomalacia, which confirms earlier findings that osteoporosis is the metabolic abnormality in cholestatic liver disease.
Diagnosis
Magnetic resonance cholangiopancreatography (MRCP) is increasingly used to diagnose PSC. Thick-slab MRCP showed good visualization in more ducts (84% vs 70%) and more strictured ducts (47% vs 36%) than contrast cholangiography but the differences were not significant [23] . MRCP was superior for intrahepatic biliary duct visualization. Good interobserver agreement was noted, with greatest agreement for extrahepatic ductal strictures. Another study by the same group validated the results of this former study [24] . The interobserver agreement for stricture detection was 61% for MRCP and 76% for endoscopic retrograde cholangiopancreatog-raphy (ERCP). However, strictures were better detected in peripheral ducts with MRCP than with ERCP. It is tempting to conclude from these and other studies that MRCP should be used for diagnosis of PSC. However, because of differences in MR equipment between hospitals and lack of standardization of this new technology it is still too early for it to replace ERCP for the diagnosis of PSC.
Complications
Primary sclerosing cholangitis has been considered a premalignant condition [25] . The risk for cholangiocarcinoma in PSC is well established. Cumulative incidence of malignancies in 604 Swedish patients with PSC and standard incidence ratio in comparison with the general Swedish population have been studied [26•]. Using the Swedish Cancer and Death Registry, these researchers demonstrated that the risk for hepatobiliary malignancies was increased 161 times, for pancreatic carcinoma 14 times, and for colorectal carcinoma 10 times compared with that of the general population. A total of 37% of all hepatobiliary malignancies were diagnosed less than 1 year after the diagnosis of PSC. A joint study from five European countries showed similarly that 50% of cholangiocarcinomas in patients with PSC were diagnosed within 1 year after diagnosis of PSC [27] . Thus, longstanding PSC is not a prerequisite for development of cholangiocarcinoma. It seems, therefore, reasonable to have a high index of suspicion for cholangiocarcinoma during the first year after the diagnosis. In these European patients, cholangiocancer was diagnosed in 27% of patients at the time of intended liver transplantation. No single diagnostic method, however, has been developed with acceptable sensitivity and specificity for the detection of cholangiocarcinoma in PSC. Several groups have tried to increase the diagnostic accuracy by a combination of different diagnostic tests to detect cholangiocarcinoma, such as CA-19-9 and brush cytology [28] and cancer markers (CA-19-9 and CEA) as well as brush cytology and DNA analysis of bile [29] . However, none of these studies [28] [29] [30] have solved the diagnostic dilemma of cholangiocarcinoma in PSC. Improvement in diagnostic tools to detect cholangiocarcinoma in PSC remains a challenge for researchers in this field.
The nature of PSC as a premalignant condition was further highlighted by a recent meta-analysis of the occurrence of colorectal cancer in PSC [31] . The meta-analysis of 11 studies demonstrated an increased risk of colorectal dysplasia and carcinoma compared with patients with UC alone. Thus, it seems reasonable to recommend a more intensive colonoscopic surveillance in patients with PSC and UC. Furthermore, a study from the Mayo Clinic reported that gallbladder polyps are frequently (40% to 60% of cases) malignant [32] . Of the 102 patients with PSC who had cholecystectomy, 14 (13.7%) had a gallbladder mass. Among those with a gallbladder mass, 57% had adenocarcinoma and the others had benign masses. In those with primary gallbladder carcinoma, a favorable outcome after cholecystectomy was shown with a 36month survival of 66%.
Treatment
An effective medical treatment of PSC demonstrating effects on hard endpoints (eg, survival, progression to cirrhosis, and the incidence of cholangiocarcinoma) is still lacking. Pirfenidone, a new antifibrotic factor, was tested for 1 year in a pilot study in 24 patients with PSC [33] . No effects were observed on biochemistry, histology, and cholangiography, and the Mayo risk score did not change with treatment. Stiehl et al. prospectively assessed the benefits of endoscopic dilatations of dominant strictures in PSC combined with ursodeoxycholic acid [34] . Dominant strictures were observed in 53% of patients during follow-up; these were dilated and all patients were treated with ursodeoxycholic acid. Survival free of transplantation was better than predicted by the Mayo multicenter survival model. However, this was an uncontrolled study and the value of endoscopic dilatations of dominant strictures in PSC cannot be answered by this study. Further randomized, controlled studies of endoscopic therapy in PSC are needed to clarify this issue.
